Significant Study on ForsLean® Published in Obesity Research

forslean-newsletter
October 31, 2005

A study published in the peer-reviewed medical journal “Obesity Research” reports that a twice-daily dose of 250 mg of ForsLean® significantly increased lean body mass and significantly decreased body fat in obese male subjects. This randomized, double-blind, placebo-controlled 12 weeks study examined the effect of forskolin on body composition, testosterone, metabolic rate, and blood pressure in 30 overweight and obese (BMI= 26 kg/m2) men. 15 subjects received ForsLean® (250 mg twice daily) and 15 subjects received a matching placebo. ForsLean® administration elicited favorable changes in body composition by significantly decreasing body fat percentage and fat mass as determined by DEXA, compared with the placebo group (p = 0.05).

Additionally, forskolin administration resulted in a change in bone mass for the 12-week Trial compared with the placebo group (p = 0.05). There was a trend toward a significant increase for lean body mass in the forskolin group compared with the placebo group (p = 0.097). Serum free testosterone levels were significantly increased in the forskolin group compared with the placebo group (p = 0.05). The actual change in serum total testosterone concentration was not significantly different among groups, but it increased 16.77 ± 33.77% in the forskolin group compared with a decrease of 1.08 ±18.35% in the placebo group.

View Newsletter (PDF)